-
Article
Open AccessErratum: Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder
Correction to: British Journal of Cancer (2015) 112, 1626–1635. doi:10.1038/bjc.2015.109; published online 21 April 2015 Updated online 26 May 2016: This article was originally published under a CC BY-NC-SA 4....
-
Article
Open AccessSelective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder
Radiotherapy for muscle invasive bladder cancer (MIBC) aims to offer organ preservation without oncological compromise. Neo-adjuvant chemotherapy provides survival advantage; response may guide patient selecti...
-
Article
Open AccessSecond cancer risk and mortality in men treated with radiotherapy for stage I seminoma
Patients with stage I testicular seminoma are typically diagnosed at a young age and treatment is associated with low relapse and mortality rates. The long-term risks of adjuvant radiotherapy in this patient g...
-
Article
Open AccessRandomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up
Radical three-dimensional conformal radiotherapy (CFRT) with initial androgen suppression (AS) is a standard management for localised prostate cancer (PC). This pilot study evaluated the role of dose escalatio...
-
Article
Open AccessBreast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors
Women treated with supradiaphragmatic radiotherapy (sRT) for Hodgkin lymphoma (HL) at young ages have a substantially increased breast cancer risk. Little is known about how menarcheal and reproductive factors...
-
Article
Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance
Active surveillance provides a unique opportunity to study biomarkers of prostate cancer behaviour, although only small volumes of tumor tissue are typically available. We have evaluated a technique for constr...
-
Article
Open AccessEvidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse
Testicular germ cell tumours (TGCTs) are the most common cause of cancer in men between the ages of 15 and 40 years, and, overall, the majority of patients should expect to be cured. The European Germ Cell Can...
-
Article
Open AccessMortality and incidence of second cancers following treatment for testicular cancer
We studied 5555 seminoma patients and 3733 patients with nonseminomatous testicular cancers diagnosed in Southeast England between 1960 and 2004. For both groups survival improved over time: 10-year relative s...
-
Article
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone
We investigated the potential for improvement in disease control by use of autologous peripheral blood stem cell transplant (PBSCT) to permit administration of high activities of 186Re-hydroxyethylidene diphospho...
-
Article
Open AccessIntensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)
New chemotherapy regimens are continuously explored in patients with high-risk malignant germ cell tumours (MGCTs). This multicentre phase II trial assessed the efficacy and toxicity of C-BOP/BEP chemotherapy ...
-
Article
Open AccessFertility, gonadal and sexual function in survivors of testicular cancer
Modern treatments cure most testicular cancer patients, so an important goal is to minimise toxicity. Fertility and sexual functioning are key issues for patients. We have evaluated these outcomes in a cross-s...
-
Article
Open AccessGemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma
There is currently no standard salvage chemotherapy regimen in relapsed and refractory lymphoma. Gemcitabine is a novel nucleoside analogue, which acts synergistically with cisplatin both in vitro and in clinical...
-
Article
Open AccessPhase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects
Radical radiotherapy is a standard form of management of localised prostate cancer. Conformal treatment planning spares adjacent normal tissues reducing treatment-related side effects and may permit safe dose ...
-
Article
Open AccessMetastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials
To study the role of single agent carboplatin chemotherapy in patients with metastatic seminoma based on the data from two randomised trials. In subgroup analyses in patients with different disease characteris...
-
Article
Open AccessSecond primary breast cancer after Hodgkin's disease
Although the potential carcinogenic risk of radiotherapy is well known, it has become clear that there is a particularly high risk of radiation-induced breast cancer in women treated for Hodgkin's disease at y...
-
Article
Open AccessRandomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer
Based on the results of combined data from three North American Phase II studies, a randomised Phase II study in the same patient population was performed, using combination chemotherapy with estramustine phos...
-
Article
Open AccessOutcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
A grading system (grades 1–3) for follicular lymphoma (FL) is used in the WHO classification for lymphoid malignancies based on the absolute number of centroblasts in the neoplastic follicles. Grade 3 FL is fu...
-
Article
Open AccessHigh activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone
We tested the feasibility and toxicity of high activities Rhenium-186 hydroxyethylidene diphosphonate, with peripheral blood stem cell rescue in patients with progressive hormone refractory prostate cancer met...
-
Article
Open AccessPre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer
Phase III studies have demonstrated the clinical benefit of adding neo-adjuvant androgen deprivation to radical radiotherapy for clinically localised prostate cancer. We have developed a nomogram to describe t...
-
Chapter and Conference Paper
Multivariate Analysis of Predictive Factors of Late Relapse in 1264 Patients with Testicular Germ Cell Tumours
10–30 per cent of patients with testicular germ cell tumours (GCTs) relapse after initial treatment. Most of these relapses happen in the first two years after treatment.
